Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis

Davies, 2016, The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences, Int J MS Care, 18, 257, 10.7224/1537-2073.2015-062 Hakiki, 2008, 'Subclinical MS': follow-up of four cases, Eur J Neurol, 15, 858, 10.1111/j.1468-1331.2008.02155.x Holloway, 2013, Estimating and communicating prognosis in advanced neurologic disease, Neurology, 80, 764, 10.1212/WNL.0b013e318282509c Johansen‐Berg, 2002, Correlation between motor improvements and altered fMRI activity after rehabilitative therapy, Brain, 125, 2731, 10.1093/brain/awf282 Kappos, 2018, Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study, Lancet, 391, 1263, 10.1016/S0140-6736(18)30475-6 Kappos, 2018, Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study, Mult Scler, 24, 963, 10.1177/1352458517709619 Katz Sand, 2014, Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis, Mult Scler, 20, 1654, 10.1177/1352458514521517 Lebrun, 2008, Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile, J Neurol Neurosurg Psychiatry, 79, 195, 10.1136/jnnp.2006.108274 Leray, 2010, Evidence for a two-stage disability progression in multiple sclerosis, Brain, 133, 1900, 10.1093/brain/awq076 Lorscheider, 2016, Defining secondary progressive multiple sclerosis, Brain, 139, 2395, 10.1093/brain/aww173 Lublin, 2014, Defining the clinical course of multiple sclerosis: the 2013 revisions, Neurology, 83, 278, 10.1212/WNL.0000000000000560 Montalban, 2017, Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, N Engl J Med, 376, 209, 10.1056/NEJMoa1606468 Ness, 2019, Differentiating societal costs of disability worsening in multiple sclerosis, J Neurol Pantano, 2002, Cortical motor reorganization after a single clinical attack of multiple sclerosis, Brain, 125, 1607, 10.1093/brain/awf164 Polman, 2011, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol, 69, 292, 10.1002/ana.22366 Polman, 2005, Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria", Ann Neurol, 58, 840, 10.1002/ana.20703 Rae-Grant, 2018, Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology, Neurology, 90, 777, 10.1212/WNL.0000000000005347 Rocca, 2002, Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage, Ann Neurol, 51, 330, 10.1002/ana.10120 Scalfari, 2010, The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability, Brain, 133, 1914, 10.1093/brain/awq118 Solari, 2019, Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany, Front Neurol, 10, 916, 10.3389/fneur.2019.00916 Spelman, 2013, Defining secondary progressive multiple sclerosis: is it possible to diagnose early?, Multiple Sclerosis Journal, 19, 38 2019, Cree BAC, Hollenbach JA, et al. Silent progression in disease activity-free relapsing multiple sclerosis, Ann Neurol., 85, 653, 10.1002/ana.25463 Weiss, 2014, Disability in multiple sclerosis: when synaptic long-term potentiation fails, Neurosci Biobehav Rev, 43, 88, 10.1016/j.neubiorev.2014.03.023 Youden, 1950, Index for rating diagnostic tests, Cancer, 3, 32, 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3